CRISPR Therapeutics
CRSP
CRSP
181 hedge funds and large institutions have $1.29B invested in CRISPR Therapeutics in 2019 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
16% more call options, than puts
Call options by funds: $30.6M | Put options by funds: $26.4M
6% more funds holding
Funds holding: 170 → 181 (+11)
2.07% more ownership
Funds ownership: 49.75% → 51.82% (+2.1%)
Holders
181
Holding in Top 10
7
Calls
$30.6M
Puts
$26.4M
Top Buyers
| 1 | +$67.4M | |
| 2 | +$38.2M | |
| 3 | +$33M | |
| 4 |
JP Morgan Chase
New York
|
+$5.78M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.71M |
Top Sellers
| 1 | -$12.6M | |
| 2 | -$12.3M | |
| 3 | -$10.6M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.42M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.36M |